Filing Flows › Cocrystal Pharma (COCP) › Q1 2026
Cocrystal Pharma (COCP) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 15, 2026
Cocrystal Pharma (COCP) reported revenue of $225K for the first quarter 2026 (Q1 2026).
Cocrystal Pharma, Q1 2026: revenue $225K, net loss $2.3M, operating cash flow −$2.3M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $225K | — | — |
| Operating profit | −$2.4M | — | — |
| Net earnings | −$2.3M | — | — |
| Operating cash flow | −$2.3M | — | — |
What changed
Revenue was $225K in Q1 2026.
Operating costs exceeded revenue by $2.4M, an operating margin of -1047.1%. The quarter ended with a net loss of $2.3M.
Operating cash flow was −$2.3M. Non-cash charges added back $12K of depreciation and amortization and $84K of share-based compensation. Working capital and other items used $137K.
Questions
What was Cocrystal Pharma's revenue in the first quarter 2026?
Cocrystal Pharma (COCP) reported revenue of $225K for the first quarter 2026 (Q1 2026).
Source: Cocrystal Pharma 10-Q on SEC EDGAR.